Savolitinib plus osimertinib versus chemotherapy for advanced, EGFR mutation-positive, MET-amplified non-small-cell lung cancer in China (SACHI): interim analysis of a multicentre, open-label, phase 3 randomised controlled trial.

Lu S, Wang J, Yang N, Lv D, Chen L, Wu L, Li X, Sun L, Yu Y, Jin B, Yang L, Guo Y, Xu H, Yi T, Zeng A, Dong X, Chen J, Wang Z, Niu H, Cheng Y, Pan P, Deng P, Pan H, Min X, Bai J, Liu L, Zhang T, Li J, Fan S, Shi MM, Mok T, Su W, SACHI Study Group.

Open source

DOI: 10.1016/s0140-6736(25)01811-2
Published: 2026-01-13
Container: Lancet
Publisher: Not recorded
Open access: no

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/s0140-6736-25-01811-2,
  title = {Savolitinib plus osimertinib versus chemotherapy for advanced, EGFR mutation-positive, MET-amplified non-small-cell lung cancer in China (SACHI): interim analysis of a multicentre, open-label, phase 3 randomised controlled trial.},
  author = {Lu S and  Wang J and  Yang N and  Lv D and  Chen L and  Wu L and  Li X and  Sun L and  Yu Y and  Jin B and  Yang L and  Guo Y and  Xu H and  Yi T and  Zeng A and  Dong X and  Chen J and  Wang Z and  Niu H and  Cheng Y and  Pan P and  Deng P and  Pan H and  Min X and  Bai J and  Liu L and  Zhang T and  Li J and  Fan S and  Shi MM and  Mok T and  Su W and  SACHI Study Group.},
  year = {2026},
  journal = {Lancet},
  doi = {10.1016/s0140-6736(25)01811-2},
  url = {https://doi.org/10.1016/s0140-6736(25)01811-2}
}

RIS

TY  - JOUR
TI  - Savolitinib plus osimertinib versus chemotherapy for advanced, EGFR mutation-positive, MET-amplified non-small-cell lung cancer in China (SACHI): interim analysis of a multicentre, open-label, phase 3 randomised controlled trial.
AU  - Lu S
AU  -  Wang J
AU  -  Yang N
AU  -  Lv D
AU  -  Chen L
AU  -  Wu L
AU  -  Li X
AU  -  Sun L
AU  -  Yu Y
AU  -  Jin B
AU  -  Yang L
AU  -  Guo Y
AU  -  Xu H
AU  -  Yi T
AU  -  Zeng A
AU  -  Dong X
AU  -  Chen J
AU  -  Wang Z
AU  -  Niu H
AU  -  Cheng Y
AU  -  Pan P
AU  -  Deng P
AU  -  Pan H
AU  -  Min X
AU  -  Bai J
AU  -  Liu L
AU  -  Zhang T
AU  -  Li J
AU  -  Fan S
AU  -  Shi MM
AU  -  Mok T
AU  -  Su W
AU  -  SACHI Study Group.
PY  - 2026
JO  - Lancet
DO  - 10.1016/s0140-6736(25)01811-2
UR  - https://doi.org/10.1016/s0140-6736(25)01811-2
ER  -

APA

S, L., J, W., N, Y., D, L., L, C., L, W., X, L., L, S., Y, Y., B, J., L, Y., Y, G., H, X., T, Y., A, Z., X, D., J, C., Z, W., H, N., Y, C., P, P., P, D., H, P., X, M., J, B., L, L., T, Z., J, L., S, F., MM, S., T, M., W, S., & Group., S. S. (2026). Savolitinib plus osimertinib versus chemotherapy for advanced, EGFR mutation-positive, MET-amplified non-small-cell lung cancer in China (SACHI): interim analysis of a multicentre, open-label, phase 3 randomised controlled trial.. Lancet. https://doi.org/10.1016/s0140-6736(25)01811-2

Source records

europe-pmc · retrieved 2026-09-26T19:16:59.748Z